Results from the phase 3b ALPINE study, which evaluated Aristada (aripiprazole lauroxil; Alkermes) and Invega Sustenna (paliperidone palmitate; Janssen) in patients experiencing an acute exacerbation of schizophrenia, showed that both of these long-acting injectable treatments effectively controlled schizophrenia symptoms
Luye Pharma Group announced the submission of a New Drug Application (NDA) for Rykindo (risperidone extended-release microsphere; LY03004) for Injectionto the Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder.
Products covered under the Clozapine REMS program include Clozaril (HLS Therapeutics), Fazaclo (Jazz), and Versacloz (TruPharma), in addition to all generic versions.
HP-3070 is being developed by Hisamitsu Pharmaceuticals in Japan in conjunction with its US subsidiary, Noven Pharmaceuticals.
Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.
Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.
Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.
Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.
Prior to this approval, the Aristada initiation regimen consisted of taking oral aripiprazole for 21 consecutive days starting with the first Aristada dose.
This prospective cohort study included a population-based sample of 2,539 individuals born in Denmark with an incident diagnosis of schizotypal disorder and without a previous diagnosis of schizophrenia.
